<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13173">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01763307</url>
  </required_header>
  <id_info>
    <org_study_id>EGFRI-MER-1a-HMO-CTIL</org_study_id>
    <nct_id>NCT01763307</nct_id>
  </id_info>
  <brief_title>A Study to Examine the Effect of Reconval K1 Cream to Prevent Skin Toxicity From EGFRI</brief_title>
  <acronym>EGFRI</acronym>
  <official_title>A Phase II Randomized, Double Blind, Placebo Study to Evaluate the Efficacy of Vitamin K1 Cream Treatment Compared to Placebo for the Prevention of Papulo-pustular Rash in Metastatic Colorectal Patients Receiving First Line EGFRI Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vitamin K1 cream may prevent papulopustular rash induced by EGFRI given to metastatic
      colorectal cancer patients.

      This study will prospectively accrue metastatic colorectal patients receiving EGFRI and
      treat with reconval cream half face versus placebo cream half face to study whether Vitamin
      k1 cream can prevent the typical skin eruption caused by EGFRI.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Potential reduction in skin toxicity by Vitamin K1 cream in metastatic colorectal patients treated with EGFRI</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction in numbers of papulo-pustular eruptions in the treatment fields compared to the placebo treated side. Changes in follicular eruptions, dryness/redness of skin estimated by the grading scale developed by the Multinational Association of Supportive Care in Cancer (MASCC) skin toxicity study group  4.0. Patients own experience of efficacy estimated by questionnaire.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Rash Due to Epidermal Growth Factor Receptor Inhibitors</condition>
  <arm_group>
    <arm_group_label>RECONVAL CREAM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>half face treated with RECONVAL CREAM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>half face treated with PLACEBO cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RECONVAL CREAM</intervention_name>
    <arm_group_label>RECONVAL CREAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  metastatic colon cancer patients

          -  male or female

          -  age&gt; 18

          -  treated EGFRI

        Exclusion Criteria:

          -  prior treatment  with EGFRI
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Merims, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medcial Organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hadas` Lemberg, PHD LLB</last_name>
    <phone>+972 2 6776095</phone>
    <email>lhadas@hadassah.org.il</email>
  </overall_contact>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>January 7, 2013</lastchanged_date>
  <firstreceived_date>December 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFRI</keyword>
  <keyword>COLON CANCER</keyword>
  <keyword>SKIN TOXICITY</keyword>
  <keyword>RECONVAL K1 cream</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Exanthema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
